76
|
Falcone A, Cremolini C, Loupakis F, Lonardi S, Casagrande M, Murgioni S, Salvatore L, Masi G, Fanotto V, Granetto C, Marmorino F, Ginocchi L, Ziampiri S, Grande R, Tonini G, Delfanti S, Di Donato S, Fontanini G, Boni L, Zagonel V. FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.13] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
77
|
Gardini AC, Faloppi L, Daniele B, Cascinu S, Lonardi S, Masi G, Negri F, Santini D, Silvestris N, Zagonel V, Scartozzi M. Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
78
|
Cremolini C, Antoniotti C, Loupakis F, Bergamo F, Ferrari L, Grande R, Tonini G, Masi G, Schirripa M, Bonotto M, Soldà C, Lucchesi S, rossini D, Corsi D, Ronzoni M, Llimpe FR, Fontanini G, Boni L, Zagonel V, Falcone A. Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.11] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
79
|
Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross P, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, LeBerre MA, Baumhauer A, Meinhardt G, Han G. Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.19] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|
80
|
Vivaldi C, Buccianti P, Musettini G, Bergamo F, Rizzato M, Sainato A, Martignetti A, Lucchesi S, Franceschi M, Boso C, Pasqualetti F, Ginocchi L, Di Clemente F, Gonnelli A, Urbani L, Montrone S, Maretto I, Sidoti F, Falcone A, Masi G. TRUST: Phase II trial of induction chemotherapy (CT) with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.65] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
81
|
Pisano S, Catone G, Pascotto A, Iuliano R, Tiano C, Milone A, Masi G, Gritti A. Paranoid Thoughts in Adolescents with Social Anxiety Disorder. Child Psychiatry Hum Dev 2016; 47:792-8. [PMID: 26658937 DOI: 10.1007/s10578-015-0612-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Recently, social anxiety disorder (SAD) and paranoia have been demonstrated to be closely related. However, data were primarily drawn from adult community samples or patients with schizophrenia. The present study used a cross-sectional design to evaluate a sample of adolescents with SAD (n = 30, mean age 15.3 ± 0.9 years) compared with an age- and sex-matched group of healthy controls (n = 26, mean age 15.9 ± 1.6 years). The SAD group displayed more frequent and intense paranoid thoughts than the control group (t = 4.16, p < 0.001). The level of paranoid thoughts was significantly predicted by the degree of social phobia, even after adjusting for sex and other anxiety disorders, although adjusting for depression slightly reduced the extent and significance of the prediction. A lack of awareness about the association between SAD and paranoia may lead to incorrect diagnoses (e.g. misdiagnosis of psychotic disorders), or it may negatively influence the (psycho)therapeutic process and patient outcomes.
Collapse
|
82
|
Vivaldi C, Buccianti P, Musettini G, Bergamo F, Rizzato M, Sainato A, Martignetti A, Lucchesi S, Franceschi M, Boso C, Pasqualetti F, Ginocchi L, Di Clemente F, Gonnelli A, Urbani L, Fornaro L, Montrone S, Maretto I, Balestro R, Falcone A, Masi G. TRUST: phase II trial of induction chemotherapy (CT) with FOLFOXIRI plus bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
83
|
Marmorino F, Cremolini C, Loupakis F, Salvatore L, Masi G, Barbara C, Dargenio F, Miraglio E, Ginocchi L, Antonuzzo L, Moretto R, Schirripa M, Chiara S, Banzi C, Amoroso D, Bonetti A, Martignetti A, Paris M, Boni L, Tomcikova D, Falcone A. Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
84
|
Casagrande M, Cremolini C, Zucchelli G, Bergamo F, Ferrari L, Pietrantonio F, Lonardi S, Loupakis F, Masi G, Pella N, Intini R, Salvatore L, Tomasello G, Pagani F, Pellino A, Dell'Aquila E, Ginocchi L, Milione M, Fea E, Pellegrinelli A, Falcone A. FOLFOXIRI plus bevacizumab (bev) as upfront treatment for metastatic colorectal cancer (mCRC) patients (pts) with initially unresectable liver-limited disease (LLD). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
85
|
Cremolini C, Moretto R, Masi G, Falcone A. Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients. Ann Oncol 2016; 27:1810. [DOI: 10.1093/annonc/mdw208] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
86
|
Rossini D, Casagrande M, Moretto R, Loupakis F, Cremolini C, Masi G, Borelli B, Lonardi S, Zagonel V, Aprile G, Ricci V, Grande R, Tomasello G, Ronzoni M, Allegrini G, Tonini G, Mancini M, Zaniboni A, Chiara S, Carlomagno C, Falcone A. Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
87
|
Antoniotti C, Cremolini C, Loupakis F, Bergamo F, Garattini S, Grande R, Tonini G, Masi G, Schirripa M, Bonotto M, Rumanò L, Lucchesi S, Rossini D, Corsi D, Ronzoni M, Rojas Llimpe F, Fontanini G, Boni L, Zagonel V, Delliponti L, Falcone A. Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): the phase II randomized MACBETH trial by GONO. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw331.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
88
|
Antoniotti C, Cremolini C, Loupakis F, Bergamo F, Grande R, Tonini G, Garattini Silvio K, Masi G, Battaglin F, Lucchesi S, Salvatore L, Corsi D, Di Fabio F, Banzi M, Moretto R, Sensi E, Rossini D, Tomcikova D, Fontanini G, Zagonel V, Boni L, Falcone A. O-011 Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw198.11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
89
|
Casagrande M, Moretto R, Loupakis F, Cremolini C, Masi G, Borelli B, Lonardi S, Marsico Valentina A, Salvatore L, Rossini D, Ferrari L, Ricci V, Grande R, Tomasello G, Ronzoni M, Allegrini G, Tonini G, Mancini M, Zaniboni A, Chiara S, Carlomagno C, Falcone A. PD-009 Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
90
|
Cortesi E, Masi G, Mancini M, Caponnetto S, Urbano F, Mosillo C, Scagnoli S, Notarianni E, Pelle G, Vivaldi C, Falcone A, Cianni R. P-158 Radioembolization (SIRT) as a Consolidation Treatment in Colorectal Liver Metastases after First Line Chemotherapy: Efficacy Safety. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.152] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
91
|
Marmorino F, Cremolini C, Loupakis F, Antoniotti C, Barbara C, Dargenio F, Miraglio E, Masi G, Salvatore L, Schirripa M, Borelli B, Marcucci L, Antonuzzo L, Chiara S, Banzi C, Amoroso D, Bonetti A, Martignetti A, Paris M, Boni L, Tomcikova D, Falcone A. PD-004 Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
92
|
Montrone S, Vivaldi C, Coraggio G, Cantarella M, Manfredi B, Laliscia C, Masi G, Loupakis F, Falcone A, Fabrini M, Sainato A, Pasqualetti F. EP-1298: Stereotactic radiotherapy in oligometastatic patients with lung metastasis from colon-rectal cancer. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32548-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
93
|
Cremolini C, Loupakis F, Masi G, Lonardi S, Granetto C, Mancini ML, Chiara S, Moretto R, Rossini D, Vitello S, Allegrini G, Tonini G, Bergamo F, Tomasello G, Ronzoni M, Buonadonna A, Bustreo S, Barbara C, Boni L, Falcone A. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Ann Oncol 2016; 27:843-9. [PMID: 26861604 DOI: 10.1093/annonc/mdw052] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Accepted: 02/03/2016] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND FOLFOXIRI plus bevacizumab is a valid option as upfront treatment for metastatic colorectal cancer (mCRC) patients. While several trials investigated the effect of combining bevacizumab with different chemotherapy regimens, including fluoropyrimidines monotherapy and oxaliplatin- or irinotecan-containing doublets, no randomized comparison assessing the impact of the addition of bevacizumab to FOLFOXIRI is available. PATIENTS AND METHODS A total of 122 mCRC patients received first-line FOLFOXIRI in the phase III trial by the GONO (FOLFOXIRI group) and 252 patients received first-line FOLFOXIRI plus bevacizumab in the TRIBE trial (FOLFOXIRI plus bevacizumab group). A propensity score-adjusted method was adopted to provide an estimation of the benefit from the addition of bevacizumab to FOLFOXIRI in terms of survival and activity parameters. RESULTS Patients in the FOLFOXIRI group had more frequently Eastern Cooperative Oncology Group performance status of one or two, high Köhne score, metachronous and liver-limited disease, had previously received adjuvant treatments and had their primary tumors resected. The median progression-free survival (PFS) was 12.3 months in the FOLFOXIRI plus bevacizumab group compared with 10.0 months in the FOLFOXIRI group {propensity score-adjusted hazard ratio (HR) 0.74 [95% confidence interval (CI) 0.59-0.94], P = 0.013}. This association was significant also in the multivariable model (P = 0.024). The median OS was 29.8 months in the FOLFOXIRI plus bevacizumab group compared with 23.6 months in the FOLFOXIRI group [propensity score-adjusted HR: 0.72 (95% CI 0.56-0.93), P = 0.014]. At the multivariable model, the addition of bevacizumab was still associated with significantly longer OS (P = 0.030). No significant differences in RECIST response rate (RR) [65.1% versus 55.7%; propensity score-adjusted odds ratio (OR): 1.29 (95% CI 0.81-2.05), P = 0.280], early RR [62.7% versus 57.8%; OR: 1.14 (95% CI 0.68-1.93), P = 0.619] and median depth of response (42.2% versus 53.8%, P = 0.259) were reported. CONCLUSIONS Though in the absence of a randomized comparison, the addition of bevacizumab to FOLFOXIRI provides significant benefit in PFS and OS, thus supporting the use of FOLFOXIRI plus bevacizumab as upfront treatment for mCRC patients. TRIALS' NUMBERS NCT01219920 and NCT00719797.
Collapse
|
94
|
Vergori A, Masi G, Donati D, Ginanneschi F, Annunziata P, Cerase A, Mencarelli M, Rossetti B, De Luca A, Zanelli G. Listeria meningoencephalitis and anti-GQ1b antibody syndrome. Infection 2016; 44:543-6. [PMID: 26825308 DOI: 10.1007/s15010-015-0862-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Accepted: 11/23/2015] [Indexed: 01/20/2023]
Abstract
We report the first case of Listeria monocytogenes meningoencephalitis associated with anti-GQ1b antibody syndrome in an immunocompetent adult. A prompt diagnosis, made thanks to the multidisciplinary contribution, allowed a combined therapeutic approach leading to final favourable outcome, despite several intercurrent complications.
Collapse
|
95
|
Dong S, Shappee BJ, Prieto JL, Jha SW, Stanek KZ, Holoien TWS, Kochanek CS, Thompson TA, Morrell N, Thompson IB, Basu U, Beacom JF, Bersier D, Brimacombe J, Brown JS, Bufano F, Chen P, Conseil E, Danilet AB, Falco E, Grupe D, Kiyota S, Masi G, Nicholls B, Olivares E. F, Pignata G, Pojmanski G, Simonian GV, Szczygiel DM, Woźniak PR. ASASSN-15lh: A highly super-luminous supernova. Science 2016; 351:257-60. [DOI: 10.1126/science.aac9613] [Citation(s) in RCA: 152] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
96
|
Liboni F, Palagini L, D'Acquinto G, Lenzi F, Tacchi A, Ricci F, Pfanner C, Manfredi A, Mauri M, Masi G. Methylphenidate effects on sleep after 5-months treatment in children with attention-deficit/hyperactivity disorder. a pilot study. Sleep Med 2015. [DOI: 10.1016/j.sleep.2015.02.1418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
97
|
Faloppi L, Casadei Gardini A, Masi G, Silvestris N, Loretelli C, Ulivi P, Vivaldi C, Bianconi M, Giampieri R, Bittoni A, Andrikou K, Del Prete M, Gadaleta C, Scartozzi M, Cascinu S. Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: combined analysis of VEGF and HIF-1a. Final results of the ALICE-2 study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
98
|
Falcone A, Cremolini C, Antoniotti C, Lonardi S, Ronzoni M, Zaniboni A, Tonini G, Salvatore L, Masi G, Mezi S, Tomasello G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Lupi C, Sensi E, Fontanini G, Boni L, Loupakis F. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv335.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
99
|
Barzon L, Papa A, Lavezzo E, Franchin E, Pacenti M, Sinigaglia A, Masi G, Trevisan M, Squarzon L, Toppo S, Papadopoulou E, Nowotny N, Ulbert S, Piralla A, Rovida F, Baldanti F, Percivalle E, Palù G. Phylogenetic characterization of Central/Southern European lineage 2 West Nile virus: analysis of human outbreaks in Italy and Greece, 2013-2014. Clin Microbiol Infect 2015; 21:1122.e1-10. [PMID: 26235197 DOI: 10.1016/j.cmi.2015.07.018] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Revised: 06/29/2015] [Accepted: 07/23/2015] [Indexed: 01/10/2023]
Abstract
In recent years, West Nile virus (WNV) lineage 2 has been spreading and causing disease outbreaks in humans and animals in Europe. In order to characterize viral diversity, we performed full-length genome sequencing of WNV lineage 2 from human samples collected during outbreaks in Italy and Greece in 2013 and 2014. Phylogenetic analysis showed that these WNV lineage 2 genomes belonged to a monophyletic clade derived from a single introduction into Europe of the prototype Hungarian strain. Correlation of phylogenetic data with geospatial information showed geographical clustering of WNV genome sequences both in Italy and in Greece, indicating that the virus had evolved and diverged during its dispersal in Europe, leading to the emergence of novel genotypes, as it adapted to local ecological niches. These genotypes carried divergent conserved amino acid substitutions, which might have been relevant for viral adaptation, as suggested by selection pressure analysis and in silico and experimental modelling of sequence changes. In conclusion, the results of this study provide further information on WNV lineage 2 transmission dynamics in Europe, and emphasize the need for WNV surveillance activities to monitor viral evolution and diversity.
Collapse
|
100
|
Cremolini C, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R, Zaniboni A, Tonini G, Barone C, Vitello S, Longarini R, Bonetti A, D'Amico M, Di Donato S, Granetto C, Boni L, Falcone A. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 2015; 26:1188-1194. [PMID: 25712456 DOI: 10.1093/annonc/mdv112] [Citation(s) in RCA: 142] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2015] [Accepted: 02/17/2015] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Early tumor shrinkage (ETS) and depth of response (DoR) predict overall survival (OS) in first-line trials of chemotherapy ± anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC). These associations and the predictive accuracy of response measurements for survival parameters were investigated in the phase III TRIBE trial of FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev. PATIENTS AND METHODS A landmark approach was adopted to define the assessable population. The distribution of RECIST response rate, ETS and DoR was compared in the two arms. Associations between response measurements and progression-free survival (PFS), post-progression survival (PPS) and OS were tested by univariate and multivariate Cox models. Prediction performance of each factor was estimated by C-index. RESULTS A significantly higher percentage of patients in the FOLFOXIRI plus bev arm achieved ETS ≥20%, when compared with the control arm (62.7% versus 51.9%, P = 0.025). Also the DoR was significantly higher in the triplet plus bev arm (43.4% versus 37.8%, P = 0.003). Both ETS and DoR were associated with PFS, PPS and OS at the univariate analyses and in the multivariate models stratified for other prognostic variables. Both ETS and DoR were able to predict survival as accurately as RECIST response. CONCLUSION FOLFOXIRI plus bev improves ETS and DoR when compared with FOLFIRI plus bev. Achieving rapid and deep tumor shrinkage consistently delays tumor progression and prolongs survival in patients treated with first-line chemotherapy plus bev. ETS is a promising and valuable end point for clinical trials' design deserving further investigation.
Collapse
|